Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

SP1049C is a novel anticancer agent containing doxorubicin and two nonionic pluronic block copolymers. In preclinical studies, SP1049C demonstrated increased efficacy compared to doxorubicin. The objectives of this first phase I study were to determine the toxicity profile, dose-limiting toxicity, m...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Danson, S, Ferry, D, Alakhov, V, Margison, J, Kerr, D, Jowle, D, Brampton, M, Halbert, G, Ranson, M
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2004
Assuntos:
Clinical
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409484/
https://ncbi.nlm.nih.gov/pubmed/15150584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601856
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares